IL6 and neoplasm: Therefore, we speculated that RasGRP1 may inhibit the development of liver cancer by inhibiting EGFR-SOS1-Ras-ERK signalling pathway activation to suppress the tumour-promoting effect of IL-6 during the acute inflammatory response.